Get the Stockscreener App
10.18
3.23%
-0.34
Pre-market:
10.56
0.38
+3.73%
Tempest Therapeutics Inc stock is traded at $10.18, with a volume of 19,694.
It is down -3.23% in the last 24 hours and down -0.97% over the past month.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.
See More
Previous Close:
$10.52
Open:
$10.55
24h Volume:
19,694
Relative Volume:
0.35
Market Cap:
$45.20M
Revenue:
-
Net Income/Loss:
$-43.10M
P/E Ratio:
-1.0472
EPS:
-9.7212
Net Cash Flow:
$-36.82M
1W Performance:
-4.68%
1M Performance:
-0.97%
6M Performance:
+43.18%
1Y Performance:
-14.43%
1-Day Range:
$10.16
$10.73
1-Week Range:
$10.16
$11.13
52-Week Range:
$5.3495
$15.08
Tempest Therapeutics Inc Stock (TPST) Company Profile
Name
Tempest Therapeutics Inc
Sector
Industry
Phone
415-798-8589
Address
2000 SIERRA POINT PARKWAY, BRISBANE
Compare TPST with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TPST
Tempest Therapeutics Inc
|
10.18 | 46.71M | 0 | -43.10M | -36.82M | -9.7212 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Tempest Therapeutics Inc Stock (TPST) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Apr-10-25 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Mar-14-24 | Initiated | Scotiabank | Sector Outperform |
| Feb-08-24 | Initiated | Jefferies | Buy |
Tempest Therapeutics Inc Stock (TPST) Latest News
Why Tempest Therapeutics Inc. stock appeals to dividend seekersWeekly Profit Recap & Free Long-Term Investment Growth Plans - newser.com
Ranking Tempest Therapeutics Inc. among high performing stocks via toolsJuly 2025 Movers & Breakout Confirmation Trade Signals - newser.com
Building trade automation scripts for Tempest Therapeutics Inc.July 2025 Opening Moves & Daily Momentum Trading Reports - newser.com
Is Tempest Therapeutics Inc. stock cheap at current valuationMarket Activity Report & Safe Capital Allocation Plans - newser.com
Is Tempest Therapeutics Inc. meeting your algorithmic filter criteriaJuly 2025 Institutional & Consistent Profit Alerts - newser.com
Full technical analysis of Tempest Therapeutics Inc. stockBond Market & Real-Time Stock Price Movement Reports - newser.com
Can technical indicators confirm Tempest Therapeutics Inc.’s reversalJuly 2025 PostEarnings & Safe Entry Zone Tips - newser.com
Can trapped investors hope for a rebound in Tempest Therapeutics Inc.Weekly Trade Recap & Breakout Confirmation Alerts - newser.com
Is Tempest Therapeutics Inc. stock undervalued vs historical averagesMarket Performance Recap & AI Driven Stock Price Forecasts - newser.com
How Tempest Therapeutics Inc. stock performs in interest rate cyclesJuly 2025 Short Interest & Smart Money Movement Alerts - newser.com
Will Tempest Therapeutics Inc. stock outperform Nasdaq indexJuly 2025 EndofMonth & Long-Term Safe Investment Ideas - newser.com
Using flow based indicators on Tempest Therapeutics Inc.2025 Historical Comparison & Long-Term Capital Growth Strategies - newser.com
What momentum indicators show for Tempest Therapeutics Inc. stock2025 Technical Overview & Daily Momentum Trading Reports - fcp.pa.gov.br
Published on: 2025-10-28 02:52:39 - newser.com
Tempest Therapeutics’ Promising Phase 3 Trial for Liver Cancer Treatment - TipRanks
Tempest Therapeutics and Adagene’s Promising Advances in Liver Cancer Treatment - TipRanks
Tempest Therapeutics Inc Stock (TPST) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):